The 250 mg Bottle and the Subpotent Recall
Monday afternoon: a 22 kg six-year-old with acute otitis media. The electronic prescription reads amoxicillin 400 mg/5 mL, 7.5 mL by mouth twice daily for 10 days, 150 mL. The 400 mg/5 mL is out of stock, so the pharmacist dispenses 250 mg/5 mL and types the same directions on the label: "7.5 mL twice daily." The child receives 375 mg per dose instead of 600 mg. Thursday the mother calls: the child is still febrile, and she noticed the label strength does not match the prescription in her patient portal. That afternoon a Class II subpotency recall arrives covering the lot the pharmacy used.
1. What are the immediate clinical and communication steps on Thursday's phone call?
Read the worked answer
Treat it as an active clinical problem first, a paperwork problem second.
- Do the arithmetic out loud: 7.5 mL of 250 mg/5 mL is 375 mg, versus an intended 600 mg - roughly 62% of the prescribed dose for three days. This child has been undertreated for otitis media and is still febrile.
- Same-day prescriber contact: describe exactly what was dispensed, the dose actually received, and the duration of fever. The prescriber needs to reassess for treatment failure and complications (perforation, mastoiditis) and decide on a new regimen.
- Tell the parent plainly what happened, in person or by phone, using plain language and without deflecting. Stop the incorrect product, dispense the correct therapy at no charge, and give written dosing instructions in milliliters.
- Document in the patient record the product and strength dispensed, calculated dose, dates, who was notified, and the replacement dispensed - written the same day, not reconstructed later.
2. What reporting obligations does this event trigger - internal, state, and federal?
Read the worked answer
Internal quality program: mandatory. External: mostly discretionary, and worth doing well.
- Internal: the pharmacy's continuous quality improvement / quality-related event program should capture the error with a root-cause analysis. The system allowed a strength different from the prescription to be processed without a hard stop, and the final check did not compare product strength to the prescription.
- State: New Jersey does not require community pharmacies to report every dispensing error to the Board, but Board quality-assurance requirements make internal documentation and review obligatory. If the error were tied to a theft or significant loss of controlled substances, DEA reporting (Form 106) would apply - not here.
- Federal/voluntary: FDA MedWatch is worth filing, particularly since a recall is also in play.
- To the prescriber and patient: already done clinically; document it.
Process fixes: force a new prescription whenever the dispensed strength differs from the prescribed strength, and add an independent double-check for pediatric liquid strengths.
3. How should the Class II subpotency recall of that lot be handled?
Read the worked answer
A Class II recall still requires patient-level action here, because the defect and the error stack.
- Quarantine all remaining stock of the lot immediately, labeled and physically separated; do not dispense pending instructions.
- Identify every patient who received that lot from dispensing records - the lot may have been used for other prescriptions, including compounds.
- Notify each affected patient or their prescriber with the lot number and what the subpotency means clinically (possible treatment failure; return to prescriber if symptoms persist). Document the notifications, dates, and method.
- Return through the reverse distributor or per the manufacturer's instructions, and record the credit and the dates.
- Confirm with the manufacturer whether a recall effectiveness check (a response form) is required.
- Do not quietly shelve the product and wait for the next order.